PASG vs RARE vs KO

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus 1. 9% for The Coca-Cola Company (KO). The Coca-Cola Company (KO) offers the better valuation at 26. 1x trailing P/E (24. 3x forward), making it the more compelling value choice. Analysts rate Ultragenyx Pharmaceutical Inc. (RARE) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, The Coca-Cola Company (KO) delivered a total return of +65.

3%, compared to -98. 1% for Passage Bio, Inc. (PASG). Over 10 years, the gap is even starker: KO returned +115. 0% versus PASG's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.

23β versus Passage Bio, Inc. 's 3. 30β — meaning PASG is approximately -1512% more volatile than KO relative to the S&P 500. On balance sheet safety, Passage Bio, Inc. (PASG) carries a lower debt/equity ratio of 128% versus 133% for The Coca-Cola Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus 1. 9% for The Coca-Cola Company (KO). On earnings-per-share growth, the picture is similar: Passage Bio, Inc. grew EPS 33. 1% year-over-year, compared to 7. 3% for Ultragenyx Pharmaceutical Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

The Coca-Cola Company (KO) is the more profitable company, earning 27.

3% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps 27. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: KO leads at 28. 7% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RARE: 76.

2% to $48. 36.

In this comparison, KO (2.

6% yield) pays a dividend. PASG, RARE do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

23), 2. 6% yield, +115. 0% 10Y return). Passage Bio, Inc. (PASG) carries a higher beta of 3. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +115. 0%, PASG: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PASG (Healthcare) and RARE (Healthcare) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PASG is a small-cap quality compounder stock; RARE is a small-cap high-growth stock; KO is a large-cap quality compounder stock. KO pays a dividend while PASG, RARE do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.